For example, as noted earlier, the small fraction of NSCLC patients carrying a chromosome rearrangement resulting from an ALK mutation will have a poor outcome with conventional therapy but will do well with a personalized treatment that includes Xalkori, which is ineffective in a majority of NSCLS patients. The gene discussed is ALK; the disease is non-small cell lung carcinoma.